World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 24 January 2022
Main ID:  EUCTR2011-002067-20-DE
Date of registration: 16/02/2012
Prospective Registration: Yes
Primary sponsor: UCB Pharma SA
Public title: Study designed to assess the short- and long-term efficacy of CZP compared with Adalimumab, both when used with methotrexate (MTX) in the treatment of subjects suffering from rheumatoid arthritis that are not responding adequately to MTX. Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human TNF that has been approved for the treatment of moderate to severe active RA in the USA, the European Union, and a number of other countries worldwide.
Scientific title: A multicenter, single blind, randomized parallel group study to assess the short and long term efficacy of certolizumab pegol plus methotrexate compared with adalimumab plus methotrexate in subjects with moderate to severe rheumatoid arthritis responding inadequately to methotrexate. - -
Date of first enrolment: 13/06/2012
Target sample size: 892
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002067-20
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: yes
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 2
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes
Countries of recruitment
Australia Austria Bulgaria Canada Czech Republic France Germany Greece
Hungary Ireland Italy Mexico Portugal Spain Switzerland United Kingdom
United States
Contacts
Name: CT Registries & Results Disclosure   
Address:  Alfred-Nobel-Strasse 10 40789 Monheim am Rhein Germany
Telephone: +492173481515
Email: clinicaltrials@ucb.com
Affiliation:  UCB BIOSCIENCES GmbH
Name: CT Registries & Results Disclosure   
Address:  Alfred-Nobel-Strasse 10 40789 Monheim am Rhein Germany
Telephone: +492173481515
Email: clinicaltrials@ucb.com
Affiliation:  UCB BIOSCIENCES GmbH
Key inclusion & exclusion criteria
Inclusion criteria:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form is signed and dated by the subject.
2. Subject is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule or medication intake according to the judgment of the Investigator.
3. Subject is =18 years of age at Screening.
4. Subject must have a diagnosis of RA at Screening, as defined by the 2010 EULAR/ACR classification criteria (Aletaha D et al, 2010).
5. Subject must have a positive rheumatoid factor (RF) and/or a positive anti cyclic citrullinated peptide antibody (anti-CCP) as determined by the central laboratory at Screening.
6. Subject must have moderate to severe RA disease at Screening and Baseline defined as:
a) Screening (all criteria required): i. =4 swollen joints (of 28 prespecified joints). ii. DAS28(ESR) >3.2. iii. CRP concentration =10mg/L (or 1.0mg/dL) and/or ESR (Westergren) =28mm/hr. b) Baseline (both criteria required): i. =4 swollen joints (of 28 prespecified joints). ii. DAS28(ESR) >3.2.
7. Subject is considered by the Investigator to be responding inadequately to treatment with MTX. An inadequate response to MTX is based on the opinion of the Investigator and following a minimum 12-week course of MTX therapy prior to the Screening Visit.
8. Subject is using MTX 15 to 25mg/week orally or subcutaneously at Screening and has used the same MTX regimen (dose and route) for a minimum of 28 days prior to Baseline
9. If using oral corticosteroids at Baseline, the subject is using a stable dose of =10mg (unchanged for at least 28 days prior to Baseline). However, when deemed clinically necessary, 1 dose adjustment of no more than ±2.5mg during the 28 days prior to Baseline is acceptable provided the total dose does not exceed 10mg.
10. The subject, if female, must be either postmenopausal for at least 1 year, surgically sterile, or practicing an acceptable method of contraception, such as:
a. oral / parenteral / implantable hormonal contraceptives, intrauterine device, or barrier and spermicide.
b. Subjects must agree to use adequate forms of contraception from Screening through at least 10 weeks (or longer if required by local regulations as reflected by local product labelling) after the final dose of IMP.
c. Male subjects must agree to ensure they or their female partner(s) use adequate contraception from Screening through at least 10 weeks (or longer if required by local regulations as reflected by local product labelling) after the final dose of IMP. Note: Abstinence is not an acceptable method of
contraception; therefore, subjects engaging or intending to engage in sexual activity must agree to employ 1 of the aforementioned acceptable methods of contraception.
11. Subject must have completed the Washout Periods for analgesics and nonbiologic DMARDs (except MTX) in accordance with Table 6.1 of the protocol.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 446
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 446

Exclusion criteria:
1. Subject has previously participated in this study (except when rescreening criteria apply) or subject (sbj) has received treatment with any biologic DMARD or has received treatment with cyclophosphamide,chlorambucil,Janus kinase,spleen tyrosine kinase or phosphodiesterase 4 inhibitors or investigational agents such as spleen tyrosine kinase. 2. Sbj was randomized in another study of medication or a med. device within the previous 3 months or is currently participating
in another study of a medication or med. device under investigation
[Criterion 3-4-5-6: please refer to the protocol – not modified by this amendment]
7. Sbj must not have a diagnosis of any other inflammatory arthritis (eg psoriatic arthritis, ankylosing spondylitis or systemic lupus erythematosus/lupus nephritis) or have a Steinbrocker IV functional
capacity. Sbj with Sjogren's Syndrome, as assessed by the PI to be limited to mild or moderate sicca symptoms that are considered to be a manifestation of secondary Sjogren's Syndrome related to RA, may be enrolled. However, systemic manifestations attributable to primary Sjogren's Syndrome are still considered exclusionary
8. Sbj must not have received any experimental biological or nonbiological therapy for immuno inflammatory indications
9. The subject may not use prohibited medications and may only use (if needed) medications within protocol defined limitations as outlined in IC 11 and Table 6.1
10. Sbj with active malignancy or a history of cancer. Exceptions are subjects with: no more
than 2 basal cell carcinomas excised prior to study entry - cervical carcinoma in situ successfully surgically treated more than 5 yrs prior to Screening
11. Sbj with a history of a lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoproliferative disease
12. Sbj with a history of blood dyscrasias
13. Sbj with a recent history or existing condition, as determined by the PI, of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac,
neurological, or cerebral disease or other significant immunological/inflammatory disease including but not limited to inflammatory bowel disease
[Criterion 14-15-16-17-18-19: please refer to the protocol - not modified by this amendment]
20. Sbj with a history or active systemic/respiratory infection due to fungal, parasitic, or
mycotic pathogens including but not limited to histoplasmosis, coccidiosis, paracoccidiosis, pneumocystis, blastomyces, aspergillus and nontuberculus mycobacteria. Radiographic findings suggestive of infections such as apical fibrosis, pleural thickening, pulmonary nodules (including any pulmonary nodules of unspecified significance), fibrotic scars, calcified granulomas, upper lobe infiltrates, cavitations and pleural effusions, calcified lung nodules, calcified hilar lymph nodes, and
pericardial calcification or any other finding that could be suggestive of inactive TB or active TB, are sufficient grounds for exclusion. Radiographs will be assessed by a radiologist whose review of the
radiograph includes a deliberate assessment of the presence or absence of TB infection, granulomatous disease, etc. Any abnormal radiographic findings should be discussed with the Sponsor and/or Medical Monitor prior to subject enrollment
21. Sbj with a history of chronic or recurrent infections such as: - more than 3 episodes requiring antibiotics or antivirals during t


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Moderate to severe rheumatoid arthritis
MedDRA version: 18.1 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859
Intervention(s)

Trade Name: Cimzia
Product Name: Certolizumab pegol
Product Code: CDP870
Pharmaceutical Form: Solution for injection
INN or Proposed INN: CERTOLIZUMAB PEGOL
CAS Number: 428863-50-7
Current Sponsor code: CDP870
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe
Route of administration of the placebo: Subcutaneous use

Trade Name: Humira
Product Name: Adalimumab
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: ADALIMUMAB
CAS Number: 331731-18-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-

Primary Outcome(s)
Timepoint(s) of evaluation of this end point: 1) Week 12
2) Week 104
Primary end point(s): 1) Percentage of subjects meeting ACR20 criteria [American College of Rheumatology 20% criteria] in the CZP+MTX randomized group compared with the ADA+MTX randomized group;
2) Percentage of subjects with DAS28(ESR) LDA [Disease Activity Score-28 joint count(erythrocyte sedimentation rate) Low disease activity] in the CZP+MTX randomized group compared with the ADA+MTX randomized group (Group A versus Group C using all randomized subjects in the FAS)
Secondary Objective: • To investigate whether a Week 12 decision point is better at predicting the long term (Week 104) treatment success with CZP+MTX as compared with a Week 12 decision point with ADA+MTX
• To compare the percentage of subjects who meet ACR20 criteria at Week 6 between the CZP+MTX- and ADA+MTX randomized arms
• To compare the percentage of subjects with DAS28(ESR) LDA at Week 6, 12 and 52 between the CZP+MTX- and ADA+MTX randomized arms
• To evaluate the percentage of subjects reaching DAS28(ESR) LDA at Week 104 in subjects responding (in accordance with the Week 12 Responder definition) at both Week 6 and Week 12 when treated with CZP+MTX compared with ADA+MTX
• To compare physical function at Week 104 between the CZP+MTX- and ADA+MTX-randomized arms
• To evaluate the time to discontinuation in Week 12 Responders treated with CZP+MTX versus ADA+MTX
Main Objective: The primary objectives of this study in adult subjects with moderate to severe RA responding inadequately to MTX are as follows:
• To demonstrate the superiority of short term (Week 12) treatment in CZP+MTX randomized subjects as compared with ADA+MTX randomized subjects
• To demonstrate the superiority of long term (Week 104) treatment in CZP+MTX randomized subjects as compared with ADA+MTX randomized subjects, with subjects who switch treatment (Week 12 Non Responders) counted as treatment failures.
Secondary Outcome(s)
Timepoint(s) of evaluation of this end point: 1) Week 104
2) Week 6
3) Week 12
4) Week 104
5) Week 52
Secondary end point(s): Among the others:
1) The percentage of subjects with DAS28(ESR) LDA at Week 104 comparing the Week 12 Responder groups (Group A versus Group C).
2) The percentage of subjects with DAS28(ESR) LDA at Week 6 using all subjects, comparing the CZP+MTX randomized arm and the ADA+MTX randomized arm
3) The percentage of subjects with DAS28(ESR) LDA at Week 12 using all subjects, comparing randomized treatment groups CZP+MTX and ADA+MTX
4) The percentage of subjects with DAS28(ESR) LDA at Week 104 comparing the Week 12 Responder groups (Group A versus Group C), who also responded at Week 6 (ie, DAS28(ESR) =3.2 or a DAS28(ESR) CFB reduction of =1.2)
5) The percentage of subjects with DAS28(ESR) LDA at Week 52 using all subjects, comparing randomized treatment groups CZP+MTX and ADA+MTX (where subjects who switch treatment at Week 12 are considered non-responders at Week 52)
Secondary ID(s)
RA0077
Source(s) of Monetary Support
UCB Pharma SA
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 13/06/2012
Contact:
Results
Results available: Yes
Date Posted: 09/12/2016
Date Completed: 13/01/2016
URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002067-20/results
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history